Saad Usmani Discusses Effective Treatment for Multiple Myeloma
By Saad Z. Usmani, MD, MBA, FACP - Last Updated: November 14, 2022Janssen and Legend Biotech announced new efficacy and safety data for BCMA-directed CAR-T cell therapy cilta-cel in the treatment of relapsed or refractory multiple myeloma. The FDA recently granted priority review of cilta-cel’s biologic license application. The data were presented at this year’s ASCO 2021 Annual Meeting. Multiple Myeloma Today spoke with Saad Usmani, MD, one of the study’s investigators, to discuss these findings.
Advertisement
Advertisement
Related Posts
ISB 2001, a novel BCMA-targeting trispecific antibody, showed increased expression of T-cell activation cell surface markers.
A QSP model of ISB 2001, a novel trispecific antibody, offers an effective pathway for designing phase 1 studies.
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
Dr. Parekh discussed the promising future of trispecifics, the group of patients with the largest unmet need, and more.
Investigators assert clinical trial design features may have contributed to this antibody-drug conjugate's loss of approvals.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.